WuXi AppTec Releases New Mobile App for Compounds Sourcing

SHANGHAI, Feb. 18, 2016 /PRNewswire/ -- WuXi AppTec (WuXi), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, announced the launch of the LabNetwork mobile app. The app gives chemists and sourcing professionals the ability to search a massive database of research chemicals, including novel building blocks, screening compounds, and more.

LabNetwork's app is the first to offer products from hundreds of emerging chemical suppliers, with supply chain transparency and full transactional and delivery capabilities. The LabNetwork database, which currently includes more than 3.3 million compounds from over 300 suppliers, is continuously growing and is expected to carry products from more than 600 suppliers by the end of 2016.

The app allows chemists to search by molecular structure drawing or keyword and to perform other actions such as filtering results, building a shopping cart, and reviewing orders. By offering the LabNetwork mobile app along with its V-Lab app, which allows chemists to request organic synthesis from their mobile device, WuXi now offers two useful tools to the global research community in the sourcing and procurement of readily available chemicals and custom synthesis of small-molecule compounds.

"With the LabNetwork app, WuXi is pleased to introduce yet another mobile tool to enable innovation-on-the-go," said Dr. Steve Yang, Executive Vice President and Chief Operating Officer of WuXi AppTec. "As a recognized leader in premier chemistry services, we are committed to integrating best-in-class R&D capabilities with cutting-edge technologies such as the LabNetwork and V-Lab mobile apps."

The LabNetwork app can be downloaded to an Apple or Android mobile device at: https://www.labnetwork.com/frontend-app/p/#!/mobileApp.

About WuXi AppTec 

WuXi AppTec is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.

For more on LabNetwork, please visit www.labnetwork.com.

For more on WuXi AppTec, please visit www.wuxiapptec.com.

For more information, please contact:                                           

Aaron Shi 
Director of Corporate Communications
+86-21 5046-4362 
[email protected]

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.